基于整合药理学平台探究参苓白术散治疗2型糖尿病的物质基础和作用机制  

Material Basis and Mechanism of Shenling Baizhusan for Treatment of Type 2 Diabetes Based on Integrated Pharmacological Platform

作　　者：张栎婧 战丽彬[1] ZHANG Li-jing;ZHAN Li-bin(Modern Research Laboratory of Spleen Visceral Manifestations Theory,School of Basic Medical,Nanjing University of Chinese Medicine,Nanjing 210023,China)

机构地区：[1]南京中医药大学中医脾藏象现代研究实验室基础医学院

出　　处：《中国实验方剂学杂志》2018年第21期157-162,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家自然科学基金项目(81230084,81730111);江苏高校优势学科建设工程项目(中西医结合)

摘　　要：目的：探究参苓白术散治疗2型糖尿病的＂成分-靶点-疾病＂相关关系。方法：利用中药整合药理学计算平台搜索参苓白术散中所有药物相关的活性成分及潜在靶点,并搜索2型糖尿病疾病靶标,二者进行富集分析。结果：参苓白术散有499个药物化学成分,药物之间可能有较强的协同作用,经过基因本体数据库和京都基因与基因组百科全书数据库富集结果显示,其化学成分对应的关键靶点定位于细胞质、线粒体、髓鞘等,参与调控腺嘌呤核苷三磷酸结合、蛋白激酶活性等1 481个生物过程、基因功能,并参与嘌呤代谢、核苷酸代谢、神经系统等179个相关通路来治疗2型糖尿病。结论：本研究通过中药整合药理学平台筛选出了参苓白术散的化学成分,并预测出其治疗2型糖尿病的作用靶点和相关通路,可能与糖脂代谢、能量代谢等密切相关,为阐明其抗2型糖尿病的分子机制奠定基础,对深入挖掘和开发经典名方参苓白术散具有重要意义。Objective： To explore the relationship of ＂component-target-disease＂of Shenling Baizhusan on treatment of type 2 diabetes with integrated pharmacological method. Method： Active ingredients and potential targets of all herbs in Shenling Baizhusan were searched by integrated pharmacological method,disease targets of type 2 diabetes were searched,and their enrichment analysis was carried out. Result： There were 499 chemical compositions in Shenling Baizhusan,and there could be a strong synergistic interaction between herbs,according to the results of gene ontology database and enrichment of Kyoto encyclopedia of genes and genomes,chemical compositions of corresponding key target was located in the cytoplasm,mitochondria,myelin sheath,etc; and involved 1 481 biological processes and gene function, such as regulation of adenosine triphosphate binding,protein kinase activity,etc; and participated in 179 related pathways,such as purine metabolism,nucleotide metabolism and nervous system, to treat type 2 diabetes. Conclusion： This study screens out the chemical constituents in Shenling Baizhusan by integrated pharmacological platform of traditional Chinese medicine,and predicts its targets and related pathways for treatment of type 2 diabetes,which may be closely related to glucose and lipid metabolism,energy metabolism,etc.

关 键 词：中药整合药理学平台 参苓白术散 2型糖尿病 腺嘌呤核苷三磷酸 基因本体 协同作用 

分 类 号：R22[医药卫生—中医基础理论] R24[医药卫生—中医学]